The TME promotes tumour progression by creating an immunosuppressive environment that hampers the body’s antitumour immune response, primarily through the Nuclear Factor Kappa B (NF-κB) and Signal Transducer and Activator of Transcription 3 (STAT3) pathways. Here, NFKB1 is linked to neoplasm.